Immune-oncology-microbiome axis in lung cancer: from carcinogenesis to therapy—a narrative review
The IOM axis reveals dynamic interactions between immune cells, cancer cells, and microbes. Specific microbe-derived metabolites show promise as lung cancer biomarkers. Current microbiome-based therapy shows great potential in lung cancer treatment.
Authors
- Mengyi Shen
- Jie Yin (ORCID: https://orcid.org/0000-0002-4990-0777)
- Dong Wang (ORCID: https://orcid.org/0000-0001-7877-7440)
- Jiayan Chen (ORCID: https://orcid.org/0000-0002-5504-4057)
- Yueying Chen (ORCID: https://orcid.org/0000-0003-3083-421X)
- Tangfeng Lv (ORCID: https://orcid.org/0009-0003-0987-6770)
- C. Xu (ORCID: https://orcid.org/0000-0002-9021-6731)
Institutions
- Chinese Academy of Sciences (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tlcr-2025-737
- Citations
- 1
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.23